The clock is ticking toward the World Health Assembly in May, yet the diplomatic scaffolding required to prevent the next global pathogen catastrophe remains incomplete. World Health Organization (WHO) member states have collectively agreed to extend high-stakes negotiations on the Pathogen Access and Benefit Sharing (PABS) annex, delaying critical final decisions until late April. This extension, while framed as a commitment to consensus, underscores the profound geopolitical and economic fissures that threaten to fracture the most significant attempt at global pandemic reform in history.

The PABS system represents the beating heart of the proposed WHO Pandemic Agreement. It is designed to create a mandatory, rapid-response framework for sharing biological samples and digital sequence information of pathogens with pandemic potential. In exchange, the system mandates the fair distribution of medical countermeasures, such as vaccines, diagnostics, and therapeutics. For a world that witnessed the stark inequality of the COVID-19 vaccine rollout, where wealthy nations stockpiled supplies while developing countries in Africa and the Global South waited months, the success of this agreement is not merely a bureaucratic checkbox—it is a matter of existential survival.

The Anatomy of the PABS Standoff

The negotiations are currently stalled at the intersection of public health necessity and intellectual property rights. The central contention involves how the benefits derived from sharing pathogen data are defined and distributed. Pharmaceutical giants and several industrialized nations are hesitant to accept requirements that could force them to share technology, waive intellectual property rights, or allocate a percentage of their production at non-profit prices during a health emergency. Conversely, developing nations, led by a coalition within the African Union and other Global South blocs, argue that sharing their pathogen data without guaranteed, equitable access to the resulting life-saving products is a form of exploitative scientific colonialism.

Discussions held this past week by the Intergovernmental Working Group (IGWG) laid bare these tensions. The complexity of the issues includes the following core areas of friction:

• Digital Sequence Information (DSI) Governance: Establishing who owns the rights when a pathogen sequence is uploaded to an open-access database and subsequently used to develop a commercial product.
• Countermeasure Allocation: Developing a legally binding mechanism that forces manufacturers to reserve a set portion of vaccines and therapeutics for developing nations, rather than relying on voluntary donations.
• Transparent Governance: Ensuring the PABS system operates with oversight that prevents corporate capture or undue influence from private industry lobbyists.
• Financial Contributions: Determining how the costs of maintaining global pathogen surveillance and storage infrastructure will be shared among member states.

A History of Inequality

The urgency behind these talks is rooted in the bitter memories of 2020. During the initial wave of the COVID-19 pandemic, the global economy suffered an estimated contraction of over $10 trillion (approximately KES 1,300 trillion). Yet, the human cost was defined by who had access to protection. In Africa, where vaccination rates lagged significantly behind Europe and North America for the first year of the rollout, the pandemic exposed the fragility of global supply chains. The WHO Pandemic Agreement is, at its core, a direct response to these systemic failures.

For a reader in Nairobi, the stakes are palpable. The agreement is not an abstract diplomatic exercise but a vital hedge against future outbreaks that could devastate local economies and healthcare systems. The Kenyan government, alongside its regional partners, has advocated for a system that recognizes the contribution of the Global South in identifying and sharing pathogen data. If the PABS annex is watered down to be non-binding or commercially lenient, it will signal to the world that when the next pathogen emerges, the hierarchy of access will remain unchanged, leaving the most vulnerable populations at the back of the queue.

The Final Stretch to Geneva

With negotiations set to resume from April 27 to May 1, the Intergovernmental Working Group faces a truncated timeline. The Bureau Co-Chairs, Ambassador Tovar da Silva Nunes of Brazil and Matthew Harpur of the United Kingdom, have urged member states to focus on the power of trust. However, trust is currently in short supply. Developing nations are wary that the extension is a tactic to erode ambition, while some Western powers remain concerned about the impact on private sector innovation and the global drug trade.

The agreement must ultimately satisfy two competing demands: it must be sufficiently robust to ensure equity, yet flexible enough to encourage pharmaceutical companies to continue investing in the research and development of countermeasures. If the PABS system fails to find this equilibrium, the WHO risks passing a toothless document that offers only the illusion of security. The world is watching to see whether diplomacy can triumph over national interest before the World Health Assembly convenes, or if the lessons of the last pandemic will be lost to the inertia of the status quo.

Whether the international community can bridge these fundamental ideological gaps by May remains the defining question of current global health policy. Failure to reach a robust, binding accord would leave the world dangerously exposed, repeating the errors of the past under the guise of an agreement that may look comprehensive on paper but fail the test of reality when the next contagion arrives.